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Introduction: Avastin Biomarkers In lunG And 3D Innovative 
anaLysis (ABIGAIL), which is a phase II, open-label, randomized 
study, investigated correlations between biomarkers and best overall 
response to bevacizumab plus platinum-doublet chemotherapy for 
patients with advanced/recurrent non–small-cell lung cancer.
Methods: Patients received bevacizumab (7.5 or 15 mg/kg, 3-weekly 
until disease progression/unacceptable toxicity) plus carboplatin/
gemcitabine or carboplatin/paclitaxel (maximum six cycles). Plasma 
samples (baseline/throughout treatment) were analyzed for vas-
cular endothelial growth factor (VEGF)-A (baseline only), VEGF 
receptors (VEGFR-1/VEGFR-2), basic fibroblast growth factor, 
E-selectin, intercellular adhesion molecule-1, and placental growth 
factor (baseline only). Tumor samples (primary specimen) were 
analyzed for VEGF-A, VEGFR-1/VEGFR-2, neuropilin (NRP), 
and CD31. Response was evaluated at baseline and every 6 weeks 
(Response Evaluation Criteria in Solid Tumors).
Results: Patients were randomized to receive chemotherapy plus 
7.5 mg/kg (n = 154) or 15 mg/kg (n = 149) bevacizumab. For the 
primary analysis, none of the baseline plasma biomarkers corre-
lated with best overall response. Exploratory analyses showed that 
low VEGF-A levels were associated with longer progression-free 
survival (7.4 versus 6.1 months; hazard ratio, 1.57; 95% confidence 
intervals, 1.17 to 2.09; p = 0.002) and overall survival (19.8 versus 
11.1 months; hazard ratio, 1.57; 95% confidence interval, 1.15–2.13; 
p = 0.004) compared with these in high baseline plasma VEGF-A 
levels. No plasma biomarkers changed significantly over time. No 
significant correlations were observed between tumor biomarkers 
and clinical outcomes. No new safety signals were observed.
Conclusion: Baseline and/or dynamic changes in plasma basic fibro-
blast growth factor, E-selectin, intercellular adhesion molecule-1, 
placental growth factor, VEGFR-1 and VEGFR-2, and tumor bio-
markers did not correlate statistically with treatment outcomes for 
bevacizumab plus chemotherapy. Only baseline plasma VEGF-A 
was significantly correlated with progression-free survival/overall 
survival.
Key Words: Non–small-cell lung cancer, Biomarker, Bevacizumab, 
Vascular endothelial growth factor.
(J Thorac Oncol. 2014;9: 848–855)
Patients with advanced-stage non–small-cell lung cancer (NSCLC) typically receive first-line platinum-based che-
motherapy, with a median overall survival (OS) consistently 
less than 12 months.1,2 NSCLC is a heterogeneous disease of 
several histological subtypes and molecular profiles, which 
may explain the limited efficacy of platinum-based chemo-
therapy in an unselected population. Multiple pathways play 
a role in the pathogenesis and progression of lung tumors; 
however, only mutations in the epidermal growth factor 
receptor and echinoderm microtubule-associated protein-like 
 4-anaplastic lymphoma kinase fusions are currently used to 
guide therapy. Because only a proportion of NSCLC tumors 
harbor these oncogenic driver mutations, chemotherapy-
based treatment has remained the standard for most patients 
without these known biomarkers.
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Bevacizumab is an antivascular endothelial growth fac-
tor (VEGF) monoclonal antibody with activity in multiple 
tumor types. In unselected patients with advanced nonsqua-
mous NSCLC, first-line combination therapy with bevaci-
zumab (15 mg/kg per 3-weekly) and carboplatin/paclitaxel 
demonstrated OS, progression-free survival (PFS), and objec-
tive response rate (ORR) improvements over chemotherapy 
alone.3 PFS and ORR improvements were also reported for 
bevacizumab (7.5 or 15 mg/kg per 3-weekly) in combination 
with cisplatin/gemcitabine, compared with chemotherapy 
alone.4 Currently, no validated biomarker for bevacizumab is 
known, but several candidate biomarkers have been examined. 
A correlation between plasma VEGF and ORR was demon-
strated for bevacizumab in NSCLC5 and other cancers (breast, 
colon, gastric, and pancreatic).6–10 Other angiogenesis bio-
markers, including E-selectin, intercellular adhesion molecule 
(ICAM-1), and fibroblast growth factor (FGF), have potential 
correlations with treatment outcome in patients with NSCLC.5 
Those markers were examined as part of the comprehensive 
biomarker research program implemented across multiple 
tumor types, which aimed to identify patients who may benefit 
most from receiving bevacizumab therapy.
Avastin Biomarkers In lunG And 3D Innovative anaLy-
sis (ABIGAIL; BO21015) was the first study to prospectively 
investigate the correlation between plasma biomarkers and best 
overall response (BOR) to bevacizumab plus  platinum-doublet 
chemotherapy for patients with advanced/recurrent NSCLC. 
The primary objective was to correlate BOR with baseline 
plasma levels of VEGF-A, VEGF receptors (VEGFR-1 and 
VEGFR-2), basic FGF (bFGF), E-selectin, ICAM-1, and 
placental growth factor (PlGF). In keeping with a European 
Union postapproval requirement, exploratory analyses of effi-
cacy and safety for the 7.5 and 15 mg/kg 3-weekly doses of 
bevacizumab plus carboplatin-based chemotherapy were per-
formed. This article describes the primary analyses (baseline 
plasma biomarker protein levels), secondary measures of effi-
cacy and safety of the two bevacizumab doses, and the explor-
atory end points (changes in biomarker levels and correlative 
analyses of tumor markers).
PATIENTS AND METHODS
Study Design and Patients
ABIGAIL was an international, multicenter,  open-label, 
randomized, phase II trial in chemonaive patients with 
advanced/recurrent nonsquamous NSCLC. Patients received 
bevacizumab plus carboplatin/gemcitabine or carboplatin/
paclitaxel, at the investigator’s discretion.
Eligible patients were randomized (centralized 
stratified assignment) to receive bevacizumab (Avastin®; 
F. Hoffmann-La Roche, Basel, Switzerland) 7.5 or 15 mg/kg 
plus chemotherapy. Stratification factors were chemotherapy 
regimen, disease stage (IIIB/IV/recurrent), sex, and Eastern 
Cooperative Oncology Group performance status. According 
to investigators’ preference, chemotherapy was either carbo-
platin (area under the curve × 5) on day 1 plus gemcitabine 
1200 mg/m2 on days 1 and 8 or carboplatin (area under the 
curve × 6) on day 1 plus paclitaxel 200 mg/m2 on day 1. The 
chemotherapy regimens were selected to allow compliance 
with the Sponsor’s regulatory commitments and to allow for 
differences in clinical practice and patient comorbidities. 
Only two regimens were permitted to reduce the potential 
impact that different chemotherapy regimens might have on 
the primary biomarker end point. A balance of chemotherapy 
regimens and baseline patient characteristics between the 
treatment arms was important; therefore, chemotherapy regi-
men was included as a stratification factor for randomization. 
Chemotherapy was given for up to six cycles at 3-weekly inter-
vals unless progressive disease (PD) or unacceptable toxicity 
was observed. Bevacizumab was administered concurrently 
with chemotherapy on day 1 of each cycle and continued as 
monotherapy until PD/unacceptable toxicity. Crossover from 
gemcitabine to paclitaxel and vice versa was not permitted.
Patients aged 18 years or older with histologically/
cytologically confirmed stage IIIB/IV, chemonaive, meta-
static, or recurrent nonsquamous NSCLC were enrolled 
between September 2008 and November 2009. Patients had 
Eastern Cooperative Oncology Group performance status 0/1 
and measurable disease as assessed by Response Evaluation 
Criteria in Solid Tumors v1.0. Exclusion criteria included the 
following: prior chemotherapy with another systemic anti-
cancer agent; clinical evidence of central nervous system 
metastases; history of grade 2 or more hemoptysis; evidence 
of tumor invading or abutting major blood vessels; malignan-
cies other than NSCLC within 5 years before randomization 
other than adequately treated cancer in situ of the cervix, basal 
or squamous-cell skin cancer, localized prostate cancer, or 
ductal carcinoma in situ; clinically significant cardiovascular 
disease; uncontrolled hypertension; current or recent use of 
aspirin (>325 mg/day); or full-dose anticoagulants or throm-
bolytic agents.
The trial was approved by local independent ethics 
committees and was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and Guidelines of Good 
Clinical Practice. This study is registered with ClinicalTrials.
gov (NCT00700180).
Biomarker Sample Collection
Samples were prospectively collected and analyzed 
according to protocol. Patients provided mandatory plasma 
samples (5 ml of blood in ethylenediaminetetraacetic acid) 
at: baseline; every second cycle during combination treat-
ment; completion of the sixth cycle; every cycle for 4 
months and thereafter every second cycle during bevaci-
zumab monotherapy; and at PD. A mandatory baseline 3 ml 
whole-blood sample for clinical genotyping/DNA analysis 
was provided. Baseline tumor samples from initial diagno-
sis were collected (where available) as paraffin-embedded 
tissue blocks or 20 tissue sections or more as unstained, 
uncovered slides.
Biomarker Assessments and Methodology
The candidate plasma biomarkers were VEGF-A, 
VEGFR-1, VEGFR-2, bFGF, E-selectin, PlGF, and  ICAM-1. 
Plasma samples (except PlGF) were analyzed centrally 
(Roche Diagnostics Ltd., Penzberg, Germany) using 
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immunological multiparametric chip technique technology, 
a Roche proprietary multiplex enzyme-linked immunosor-
bent assay platform. Plasma VEGF-A was measured at base-
line only, as the assay does not reliably measure VEGF-A 
during bevacizumab treatment.
Plasma PlGF analysis was performed centrally 
(Covance Central Laboratory Services Inc., Indianapolis, IN) 
using enzyme-linked immunosorbent assay (Quantikine®; 
R&D Systems, Minneapolis, MN) and environmental impact 
assessment methodology on a Bio-Tek ELx800 automated 
microplate reader. Tumor tissue biomarkers (VEGF-A, 
VEGFR-1, VEGFR-2, NRP-1, and CD31 [microvessel den-
sity]) were analyzed centrally (Targos Molecular Pathology, 
Kassel, Germany). Immunohistochemistry was performed on 
5-μm sections of paraffin-embedded tissue. To assess tissue 
biomarker expression, an H-score was calculated for each 
sample other than CD31.
Safety and Efficacy Assessment
Tumors were investigator-evaluated (according to 
Response Evaluation Criteria in Solid Tumors) at baseline 
and 6-weekly (i.e., every two cycles) during the trial. Patients 
who withdrew from the trial (excluding for PD) were assessed 
at 6-weekly intervals until PD. Tumor size was assessed 
using high-resolution computed tomography scans, obtained 
according to a prespecified acquisition protocol. An inde-
pendent Data and Safety Monitoring Board was responsible 
for the ongoing review of unblinded safety data. Adverse 
events (AEs) were graded using the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 3.0 
and coded according to the Medical Dictionary for Regulatory 
Activities (MedDRA v14.0).
Statistical Analyses
Analysis of the primary end point and all secondary 
end points, except OS, was performed using a data cutoff of 
September 17, 2010. OS was analyzed using a data cutoff of 
July 11, 2011.
A sample size of approximately 300 patients was chosen 
to provide sufficient data to generate biomarker hypotheses 
(no formal hypothesis testing was planned or performed). 
Assuming an ORR of approximately 30%, and on the basis 
of a type α (or type I) error of 0.01 (to account for multiple 
testing), the study had 80% power to detect an odds ratio of 
greater than 2.24 for the difference in BOR between high and 
low groups.
The treatment arms were pooled for the primary analy-
sis, which predefined baseline plasma VEGF-A, VEGFR-1, 
VEGFR-2, bFGF, E-selectin, PlGF, and ICAM-1 as the pri-
mary set of biomarkers.
Plasma biomarkers were analyzed as continuous vari-
ables using a log2 transformation. Tumor biomarkers were 
analyzed as continuous variables but were not log trans-
formed. Biomarkers were dichotomized: patient populations 
were divided into high (≥ median) or low (<median) groups 
for each analysis, using the sample median plasma concentra-
tion or the sample median tumor H-score as the cutoff. PFS 
was a secondary end point, and an exploratory equivalence 
boundary was calculated as follows: in the E4599 study, 
the median PFS in the 15 mg/kg bevacizumab arm was 6.4 
months; therefore, with 15-month linear recruitment and 
10-month minimum follow-up in 300 patients, approximately 
249 events were expected. Under the assumption that the haz-
ard ratio (HR) is 1 (i.e., the treatment arms have equivalent 
PFS) with 80% power and 95% confidence, the boundaries for 
equivalence were 0.70 and 1.43.
Correlation of Plasma and Tumor 
Markers with BOR/PFS/OS
Exploratory analyses of the correlations between bio-
marker levels and the following end points were carried out: 
BOR, PFS (randomization to PD/death), and OS (random-
ization to death, irrespective of cause). The biomarker odds 
ratio was tested using Wald’s test. No formal adjustments were 
made for multiple testing. Correlation of biomarker levels with 
BOR was performed using logistic regression with correction 
for baseline prognostic factors. Multiple Cox regression mod-
els were run for PFS/OS using a similar strategy. Dynamic 
evaluation of plasma markers (change from baseline) were 
presented as box plots.
RESULTS
Patient Characteristics
Of 303 patients randomized (49 centers; 15 coun-
tries [Europe, Eastern Asia, Australia, and Canada]), 154 
received bevacizumab 7.5 mg/kg plus chemotherapy (car-
boplatin/gemcitabine or carboplatin/paclitaxel) and 149 
received bevacizumab 15 mg/kg plus chemotherapy (Fig. 1). 
Table 1 lists the baseline characteristics of the intention-to-
treat (ITT), biomarker-evaluable plasma, and biomarker-
evaluable immunohistochemistry populations. Generally, 
the  biomarker-evaluable plasma and biomarker-evaluable 
immunohistochemistry baseline characteristics were balanced 
between arms.
Primary Analysis: Correlation of Baseline 
Plasma Biomarker Level with BOR
Baseline plasma level did not correlate with response 
for any of the seven markers assessed. Table 2 summarizes the 
BOR in patients with low and high baseline biomarker levels. 
The p value for E-selectin was less than 0.05 but not statisti-
cally significant after adjustment for multiple testing.
Exploratory Analyses
Correlation of baseline plasma markers  
with efficacy parameters
Only VEGF-A at baseline seemed to significantly cor-
relate with PFS and OS (Fig. 2). Low baseline VEGF-A 
levels were associated with longer PFS (7.4 months) versus 
high baseline VEGF-A (6.1 months): HR, 1.57 (95% con-
fidence interval [CI], 1.17 to 2.09); p = 0.002. Similarly, 
low baseline VEGF-A levels were associated with longer 
median OS (19.8 months) compared with that in high base-
line VEGF-A levels (11.1 months; HR, 1.57; 95% CI, 1.15 to 
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2.13]; p = 0.004). Considering a total of seven tests, adjust-
ing for multiple testing would still result in a statistically 
significant p value.
Exploration of change from baseline plasma  
marker levels
At least one postbaseline plasma sample was available 
from approximately 74% of patients for each of the candidate 
biomarkers. Plasma biomarker levels for bFGF, E-selectin, 
ICAM-1, VEGFR-1, and VEGFR-2 were not different 
between baseline and time of progression (Supplementary 
Fig. 1, Supplementary Digital Content 1, http://links.lww.
com/JTO/A564) and were not different between baseline and 
cycles two, four, or six for any of the biomarkers tested.
Correlation of tumor protein markers with efficacy 
parameters
The percentage of patients with available tumor samples 
for analysis for each biomarker ranged from 19.5% to 30.7% 
(Supplementary Table 1, Supplementary Digital Content 2, 
http://links.lww.com/JTO/A565). There seemed to be an asso-
ciation between tumor VEGFR-1 and treatment effect. High 
tumor levels of VEGFR-1 were associated with shorter OS 
(p = 0.0371), but this was not statistically significant after 
FIGURE 1.  Patient disposition during the study. *Includes 11 patients receiving bevacizumab 7.5 mg/kg plus chemotherapy 
and 13 patients receiving bevacizumab 15 mg/kg plus chemotherapy who had prematurely withdrawn from at least one 
component of chemotherapy but had continued bevacizumab. In the bevacizumab 7.5 mg/kg + chemotherapy arm, five 
patients had bevacizumab withdrawn prematurely, four were lost to follow-up, 46 were alive in follow-up, and five were 
continuing on study treatment at data cutoff. In the bevacizumab 15 mg/kg + chemotherapy arm, seven patients had beva-
cizumab withdrawn prematurely, five were lost to follow-up, 27 were alive in follow-up, and three were continuing on study 
treatment at data cutoff.
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TABLE 1.  Baseline Characteristics of the ITT, BEP, and BEI Populations
ITT BEP BEI
Characteristic,  
n (%)
Bev 7.5 mg + Chemo  
(n = 154)
Bev 15 mg + Chemo  
(n = 149)
Bev 7.5 mg + Chemo  
(n = 144)
Bev 15 mg + Chemo  
(n =143)
Bev 7.5 mg + Chemo  
(n = 44)
Bev 15 mg + Chemo  
(n = 50)
Sex
  Female 56 (36) 55 (37) 53 (37) 55 (38) 12 (27) 20 (40)
  Male 98 (64) 94 (63) 91 (63) 88 (62) 32 (73) 30 (60)
Ethnicity
  Caucasian 131 (85) 127 (85) 122 (85) 122 (85) 36 (82) 44 (88)
  Asian 23 (15) 21 (14) 22 (15) 20 (14) 8 (18) 5 (10)
  Other 0 (0) 1 (<1) 0 (0) 1 (<1) 0 (0) 1 (2)
Smoking status
  Never smoker 49 (32) 40 (27) 49 (34) 38 (27) 14 (32) 13 (26)
  Former smoker 60 (39) 70 (47) 54 (38) 68 (48) 16 (36) 23 (46)
  Current smoker 44 (29) 39 (26) 40 (28) 37 (26) 14 (32) 14 (28)
ECOG PS
  0 56 (36) 53 (36) 52 (36) 49 (34) 16 (36) 17 (34)
  1 98 (64) 96 (64) 92 (64) 94 (66) 28 (64) 33 (66)
BEI, biomarker-evaluable immunohistochemistry; BEP, biomarker-evaluable plasma; ECOG PS, Eastern Cooperative Oncology Group performance status; ITT, intention-to-treat.
TABLE 2.  Summary of BOR, PFS, and OS by Baseline Plasma Biomarkers
BOR
Low BM Level High BM Level Logistic Regression
n Responders, % n Responders, % OR* 95% CI p Value
bFGF 142 45.07 141 42.55 1.07 0.63–1.80 0.8127
E-selectin 142 39.44 141 48.23 1.81 1.06–3.08 0.0285
ICAM 142 44.37 141 43.26 1.09 0.64–1.85 0.7478
PlGF 146 43.87 56 42.86 1.16 0.58–2.33 0.6761
VEGF-A 140 43.57 140 45.00 1.22 0.72–2.09 0.4601
VEGFR-1 142 48.59 141 39.01 0.77 0.46–1.29 0.3193
VEGFR-2 143 39.16 140 48.57 1.44 0.85–2.45 0.1758
Low BM Level High BM Level Cox Regression
PFS n Events, n (%)
Median PFS, 
Months n Events, n (%)
Median PFS, 
Months HR* 95% CI p Value
bFGF 142 116 (82) 7.2 141 124 (88) 6.5 1.21 0.92–1.59 0.170
E-selectin 142 119 (84) 6.6 141 121 (86) 6.8 0.94 0.72–1.24 0.684
ICAM 142 118 (83) 7.0 141 122 (87) 6.3 1.18 0.89–1.56 0.250
PlGF 146 122 (84) 6.7 56 51 (91) 6.3 1.20 0.85–1.71 0.308
VEGF-A 140 111 (79) 7.4 140 126 (90) 6.1 1.57 1.17–2.09 0.002
VEGFR-1 142 119 (84) 7.2 141 121 (86) 6.2 1.14 0.87–1.49 0.351
VEGFR-2 143 120 (84) 6.7 140 120 (86) 6.9 0.95 0.72–1.26 0.724
OS n Events, n (%)
Median OS,  
Months n Events, n (%)
Median OS,  
Months HR* 95% CI p Value
bFGF 142 94 (66) 17.0 141 105 (75) 13.1 1.11 0.82–1.50 0.5101
E-selectin 142 97 (68) 13.7 141 102 (72) 14.0 0.91 0.67–1.22 0.5176
ICAM 142 91 (64) 16.4 141 108 (77) 12.3 1.23 0.90–1.67 0.1934
PlGF 146 97 (66) 17.0 56 42 (75) 11.4 1.11 0.75–1.64 0.6035
VEGF-A 140 83 (59) 19.8 140 113 (81) 11.1 1.57 1.15–2.13 0.0042
VEGFR-1 142 94 (66) 17.4 141 105 (75) 11.5 1.30 0.97–1.75 0.0827
VEGFR-2 143 100 (70) 13.4 140 99 (71) 14.2 0.83 0.61–1.13 0.2435
*OR/HR: high vs. low BM level.
bFGF, basic fibroblast growth factor; BM, blood glucose monitoring; BOR, best overall response; CI, confidence interval; HR, hazard ratio; ICAM, intercellular adhesion molecule; 
OR, odds ratio; OS, overall survival; PFS, progression-free survival; PlGF, placental growth factor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
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adjustment for multiple testing. No statistically significant 
correlations were observed between the tumor markers inves-
tigated and BOR, PFS, or OS.
Correlation between tumor and plasma markers
An exploration of the correlation between patients’ 
baseline tumor VEGFR-1 expression and baseline VEGF-A 
plasma level revealed a possible correlation between the two 
(0.26, p = 0.025) (Supplementary Fig. 2, Supplementary 
Digital Content 3, http://links.lww.com/JTO/A566).
Efficacy in the Overall Population
ORR was 37.1% (7.5 mg/kg bevacizumab) versus 46.4% 
(15 mg/kg bevacizumab) (p = 0.1737). Disease control rate 
was similar between arms at 76.8% (7.5 mg/kg) and 78.5% 
(15 mg/kg; p = 0.6148). PFS was similar in the ITT popula-
tion between doses: 6.8 months (7.5 mg/kg) and 6.7 months 
(15 mg/kg): HR, 1.01; 95% CI, 0.78 to 1.31; as noted, 95% 
CI equivalence boundaries of 0.70 and 1.43 were defined. 
Supplementary Figure 3 (Supplementary Digital Content 4, 
http://links.lww.com/JTO/A567) shows subgroup analyses of 
PFS according to bevacizumab dose/chemotherapy regimen. 
Similar results to the ITT analysis were apparent in all four 
subgroups; however, this comparison was nonrandomized and 
patient numbers were small. Median OS also seemed similar 
across treatment arms (13.4 and 13.7 months for the 7.5 and 
15 mg/kg arms, respectively; HR, 1.16; 95% CI, 0.87–1.53) 
although the trial was not powered for OS.
Subsequent Systemic Antineoplastic Therapy
Second-line therapy was given to 56% and 52% of 
patients (7.5 and 15 mg/kg arms, respectively) and the most 
common regimens were pemetrexed (16% versus 13%), 
erlotinib (12% versus 14%), gefitinib (6%, both arms), and 
docetaxel (5%, both arms). A total of 18% and 10% of patients 
(7.5 and 15 mg/kg arms, respectively) received third-line ther-
apy, most often erlotinib (9% versus 4%) and pemetrexed (5% 
versus 2%).
Safety
All randomized patients who received at least one dose 
of trial treatment were included in the safety analysis. The 
median dose intensity was approximately 95% for bevaci-
zumab, carboplatin, and paclitaxel and 89% for gemcitabine.
The most common AEs were predominantly grade 1/2. 
No new safety signals were observed compared with previ-
ous NSCLC bevacizumab studies. The incidence of the most 
common grade 3 or greater AEs was broadly similar across 
the two arms, with some exceptions (Supplementary Table 
2, Supplementary Digital Content 5, http://links.lww.com/
JTO/A568). A higher incidence of pulmonary embolism 
was observed in the 15 mg/kg bevacizumab arm versus the 
7.5 mg/kg arm, whereas the 7.5 mg/kg arm had higher inci-
dences of neutropenia, thrombocytopenia, and leukopenia. 
AEs of special interest for bevacizumab are also summarized 
(Supplementary Table 2, Supplementary Digital Content 5, 
http://links.lww.com/JTO/A568). More bleeding events were 
observed with 7.5 mg/kg bevacizumab than with the higher 
dose. One patient with squamous-cell carcinoma who was 
erroneously randomized into the study (7.5 mg/kg arm) had a 
fatal pulmonary hemorrhage. The incidence of venous throm-
boembolism was higher in the 15 mg/kg group. The most 
common cause of death was disease progression.
DISCUSSION
ABIGAIL was the first prospective study on the cor-
relation between plasma biomarkers and tumor response in 
advanced NSCLC. None of the angiogenic plasma biomarkers 
investigated correlated with tumor response to chemotherapy 
plus bevacizumab. Only low baseline plasma VEGF-A level 
was correlated with longer PFS and OS. VEGF-A is the pri-
mary ligand targeted by bevacizumab and, in the absence of a 
control arm, the observed correlation could be explained by a 
prognostic and/or predictive role for the biomarker. The data 
reported here do not contradict previous studies, which report 
potential prognostic and/or predictive association of VEGF-A 
with clinical outcomes in bevacizumab-treated NSCLC and 
other tumor types.
Several studies have reported a potential prognos-
tic value of VEGF in NSCLC at tumor level.11–21 Although 
FIGURE 2. A, PFS and (B) OS relative to baseline plasma 
VEGF-A levels. CI, confidence interval; HR, hazard ratio; OS, 
overall survival; PFS, progression-free survival; VEGF, vascular 
endothelial growth factor.
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fewer studies have investigated the role of circulating VEGF 
levels as prognostic markers of patient outcomes in NSCLC 
and other tumor types,6,8,22,23 and although the data are more 
heterogeneous, the evidence is compelling. Further investiga-
tions are needed to validate these results.
The value of VEGF-A as a potential predictive marker 
for clinical outcomes with bevacizumab was also investigated. 
High plasma VEGF-A levels were predictive of increased 
response to bevacizumab plus carboplatin/paclitaxel com-
pared with carboplatin/paclitaxel alone in NSCLC patients in 
the E4599 study.5 In contrast, the predictive value of VEGF-A 
was not observed for OS in the Avastin in Lung (AVAiL) study 
of patients with NSCLC randomized to platinum-based che-
motherapy with or without bevacizumab.6,24 Plasma VEGF-A 
levels have shown potential predictive value in trials of beva-
cizumab in other tumor types. Biomarker analyses from the 
Avastin and Docetaxel (AVADO), Avastin in Gastric Cancer 
(AVAGAST), and Avastin and Tarceva in Advanced Pancreatic 
Cancer (AVITA) studies of bevacizumab plus chemotherapy 
for the first-line treatment of human epidermal growth factor 
receptor 2 (HER2)-negative metastatic breast cancer, advanced 
gastric cancer, and metastatic pancreatic cancer, respectively, 
showed that high plasma VEGF-A levels correlated with 
improved outcomes after bevacizumab treatment, indicating a 
possible predictive value.7,9,10 Interpretation of these apparently 
different results is complex. Although  true-negative results in 
NSCLC cannot be excluded, confounding factors such as sam-
ple preparation and analytical variability may have contributed 
to the conflicting intertrial findings.
Differences in analytical sensitivity may have been a 
factor in the apparently varying predictive value of VEGF-A 
across tumor types. The presence of shorter isoforms 
(VEGF-A121 and VEGF-A110), which are detected with 
greater sensitivity than longer isoforms by the immunologi-
cal multiparametric chip technique assay, may vary between 
tumor types and contribute to heterogeneity of predictive 
value across tumor type. The isoform VEGF-A189, for exam-
ple, was more frequently expressed in NSCLC (90.5%) than 
in extraneoplastic lung tissue (57.6%, p = 0.00004).21
Controversy remains regarding the question of whether 
plasma, serum, or whole blood provides the best representa-
tion of the tumor site.25–27 Patients with more than two meta-
static tumor sites or more advanced stage of disease (stage IV 
versus IIIB) tended to have higher baseline levels of plasma 
VEGF-A, suggesting that VEGF-A level may reflect tumor 
volume. It is important in the era of personalized medicine 
that clinicians reach a consensus on the preferred biospecimen 
and analytical methodology to facilitate accurate data inter-
pretation and enable cross-trial comparisons.
Other baseline plasma markers including ICAM-1, 
bFGF, VEGFR-1, VEGFR-2, PlGF, and E-selectin were not 
correlated with tumor response rate or survival. This is con-
sistent with a retrospective biomarker analysis of the E4599 
study, which reported similar findings.5 Furthermore, plasma 
biomarker levels did not change significantly over time (as 
assessed by serial measurements at cycles two, four, and 
six), thus dynamic change would have minimal predictive 
value. The results of the ABIGAIL study suggest that further 
investigation of any of these single biomarkers for bevaci-
zumab is not warranted.
The secondary efficacy outcomes of ABIGAIL were 
similar to those in the pivotal phase III E4599 and AVAiL 
studies.3,4 Median OS point estimates were comparable with 
AVAiL and E4599 (12.3–13.6 months), and the median PFS 
in ABIGAIL was similar to the median PFS for the bevaci-
zumab group in the E4599 study (6.2 months). Efficacy out-
comes for bevacizumab at the two dose levels (7.5 and 15 mg/
kg) were similar in the ABIGAIL study, but the limited sample 
size and exploratory nature of the study mean that it is not 
possible to draw formal statistical conclusions regarding the 
doses. With regard to safety, more hemorrhagic events were 
associated with the 7.5 mg/kg dose and more thromboembolic 
events with the 15 mg/kg dose. Three grade 5 hemorrhage 
events occurred, one of which was associated with a protocol 
violation. The overall incidence of bevacizumab-associated 
toxicity in ABIGAIL was similar to E4599 and AVAiL.3,4 The 
safety of the 7.5 and 15 mg/kg treatment arms seemed similar.
In summary, baseline and dynamic change in plasma 
levels of bFGF, E-selectin, ICAM-1, PlGF, VEGFR-1, and 
VEGFR-2 did not correlate with tumor response for beva-
cizumab plus chemotherapy. Low baseline plasma levels of 
VEGF-A had a statistically significant correlation with lon-
ger PFS and OS. VEGF-A may be a promising biomarker, but 
the current study cannot determine the nature of the observed 
effect, that is, whether it is predictive or prognostic, due to 
the lack of a control arm. Future randomized studies would 
be needed to further explore the potential predictive value of 
plasma VEGF-A.
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